KSPN
OUR NEW PROFILE IS: (NASDAQ: KSPN)
150 Employees, Serving 5,000 Brands in 20 Countries
The Entire Float is Under 4Million According to Yahoo Finance
Yahoo Also Has Their Revenues Over $130 Million for 2022
______________
Hello Everyone,
We have another low float profile for todays session.
Pull up KSPN Immediately and start your research.
NEWS
MANAGEMENT
Brock Kowalchuk
Lisa Wideman
Ed Sapienza
Sincerely,
MICROCAPDAILY
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS A PUBLICATION OF MICROCAPDAILY, LLC, HEREIN REFERRED TO AS MCD. MCD’S REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATIONAL PURPOSES ONLY. MCD IS ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION
WE HAVE NOT BEEN COMPENSATED IN ANY WAY FOR THIS PROFILE REGARDING KSPN. WE DO NOT OWN ANY SHARES IN THE COMANY.
BY SUBSCRIBING TO OR OTHERWISE USING THIS WEBSITE/NEWSLETTER, YOU AGREE TO HOLD MCD AND ITS OPERATORS, OWNERS, AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS, DAMAGE, OR INJURY THAT YOU MAY INCUR, MONETARY OR OTHERWISE. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AN EXTREMELY HIGH DEGREE OF RISK. NEVER INVEST IN ANY STOCK FEATURED ON MCD’S SITE OR NEWSLETTER UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING MCD’S SERVICES, JOINING MCD’S SITE OR EMAIL/BLOG LIST, OR FOLLOWING ANY SOCIAL NETWORKING PLATFORMS MCD MAY USE.PLEASE NOTE WELL: MCD IS NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER. MCD IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES AND EXCHANGE COMMISSION, OR FINRA. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED.THE INFORMATION CONTAINED HEREIN IS BASED ON INFORMATION SUPPLIED BY THE COMPANIES PROFILED, PUBLICLY AVAILABLE INFORMATION, PRESS RELEASES, AND OTHER SOURCES WHICH MCD BELIEVES TO BE RELIABLE, BUT IS NOT GUARANTEED BY MCD AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. MCD IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES PROFILED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE/NEWSLETTER IN DECIDING TO INVEST OR MAKE OTHER FINANCIAL DECISIONS. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE/NEWSLETTER AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. MCD STRONGLY ENCOURAGES READERS AND INVESTORS TO CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES, INCLUDING BY REVIEWING SEC FILINGS (FORMS 10-Q, 10-K, 8-K, 3, 4, 5, SCHEDULE 13D) AND BY CONSULTING YOUR OWN TAX, BUSINESS, FINANCIAL, AND INVESTMENT ADVISORS.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT, AND MAY BE FORWARD-LOOKING STATEMENTS. FORWARD-LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD-LOOKING STATEMENTS MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEES, EXPECTS, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, MAY, COULD, OR MIGHT. THERE IS NO GUARANTEE THAT PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS.
Source 1: https://www.globenewswire.com/news-release/2021/12/17/2354510/0/en/Cancer-Drugs-Market-Size-Worth-Around-US-272-Billion-by-2030.html
Source 2: https://www.youtube.com/watch?v=K2ZnjL0lOM8
Source 3: https://www.youtube.com/watch?v=4zDPUHxzajs
Source 4: https://www.lls.org/sites/default/files/National/USA/Pdf/LLS-CAR-T-cell-Therapy-Timeline.pdf
Source 5: http://www.avalon-globocare.com/
Source 6: https://simplywall.st/stocks/us/healthcare/nasdaq-avco/avalon-globocare
Source 7: https://www.marketwatch.com/press-release/year-end-update-for-this-up-coming-nasdaq-at-the-forefront-of-innovations-in-healthcare-featuring-ai-immunotherapies-avalon-globocare-corp-nasdaqavco-is-avco-the-next-bfri-2022-01-10
Source 8: https://bit.ly/3tZGqcI
Source 9: https://www.proactiveinvestors.com/companies/news/953526/avalon-globocare-says-senlangbio-will-enhance-its-capabilities-in-cell-and-gene-therapy-953526.html
Source 10:https://www.proactiveinvestors.com/companies/news/953526/avalon-globocare-says-senlangbio-will-enhance-its-capabilities-in-cell-and-gene-therapy-953526.html
Source 11: https://www.youtube.com/watch?v=IUlflfiMZT0
Source 12: https://finance.yahoo.com/news/avalon-globocare-announces-study-featuring-130000405.html
Source 13: https://finance.yahoo.com/news/avalon-globocare-expands-ip-portfolio-130000830.html
Source 14:https://njbmagazine.com/monthly-articles/njs-burgeoning-biotech-industry/
Source 15: https://finviz.com/quote.ashx?t=AVCO
Source 16: https://bioinformant.com/product/car-t-funding-brief/
Source 18: https://stockcharts.com/h-sc/ui?s=AVCO
Source 19: https://www.barchart.com/stocks/quotes/AVCO/price-history/historical
Source 20: https://www.tipranks.com/stocks/avco/insider-trading
Source 21: https://schrts.co/qMbaITCq
Source 22: https://www.barchart.com/stocks/quotes/ALBT/price-history/historical?orderBy=tradeTime&orderDir=desc
Source 23: https://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=ALBT&insttype=Stock
Source 24: https://www.wallstreetzen.com/how-to-buy-avalon-globocare-stock
Source 25: https://schrts.co/tujpQiHm
Source 26: https://www.marketwatch.com/investing/stock/albt?mod=search_symbol
Source 27: https://www.nasdaq.com/articles/a-small-biotech-stock-for-uncertain-times
Source 28: https://blog.tipranks.com/wp-content/uploads/2022/02/Volatile-stocks-0213-750×406.jpg
Source 29: https://ir.avalon-globocare.com/press-releases/detail/93/avalon-globocare-announces-publication-featuring-qty-code
Source 30: https://ir.avalon-globocare.com/all-sec-filings/content/0001213900-22-023156/ea159234ex99-1_avalonglo.htm
Source 31: https://ir.avalon-globocare.com/press-releases/detail/97/avalon-globocare-announces-nasdaq-ticker-symbol-change-from
Source 32: https://www.citybiz.co/wp-content/uploads/2021/06/Avalon-GloboCare.jpg
Source 33: https://www.wallstreetzen.com/stocks/us/nasdaq/albt/ownership
Source 34: https://www.proactiveinvestors.com/companies/news/997693/avalon-globocare-to-acquire-majority-interest-in-laboratory-services-mso-in-transformative-deal-worth-31m-997693.html
Source 35: https://ir.avalon-globocare.com/press-releases/detail/94/avalon-globocare-receives-allowance-for-joint-u-s-patent
Source 36: https://njbmagazine.com/monthly-articles/njs-burgeoning-biotech-industry/
Source 37: https://d4r15a7jvr7vs.cloudfront.net/ewoJICAgICAgICAgICAgICAgICJidWNrZXQiOiAiZmlsZXMubGJyLmNsb3VkIiwKCSAgICAgICAgICAgICAgICAia2V5IjogInB1YmxpYy8yMDIyLTAxL3VzcHRvIGdyYXBoIHVwIC5qcGciLAoJICAgICAgICAgICAgICAgICJlZGl0cyI6IHsKCSAgICAgICAgICAgICAgICAgICJyZXNpemUiOiB7CgkgICAgICAgICAgICAgICAgICAgICJ3aWR0aCI6IDk0NSwKCSAgICAgICAgICAgICAgICAgICAgImhlaWdodCI6IDUyNiwKCSAgICAgICAgICAgICAgICAgICAgImZpdCI6ICJjb3ZlciIKCSAgICAgICAgICAgICAgICAgIH0KCSAgICAgICAgICAgICAgICB9CgkgICAgICAgICAgICB9
Source 38:https://finance.yahoo.com/news/avalon-globocare-expands-ip-portfolio-130000830.html
Source 39: https://www.cellandgene.com/doc/cell-gene-therapies-investment-outlook-in-beyond-0001
Source 40: https://ir.avalon-globocare.com/press-releases/detail/96/avalon-globocare-signs-definitive-agreement-for
Source 41: https://finance.yahoo.com/news/avalon-globocare-announces-deployment-breakthrough-140000864.html
Source 42: https://www.businesswire.com/news/home/20220912005443/en/Leukemia-Therapeutics-Global-Market-Report-2022-A-20-Billion-Market-in-2026
Source 43: https://www.barchart.com/stocks/quotes/ALBT/price-history/historical
Source 44: https://schrts.co/QpFdGWSm
Source 45: https://nanostring.com/wp-content/uploads/iStock-980196834-1.jpg
Source 46: https://finance.yahoo.com/news/avalon-globocare-announces-closing-strategic-140000910.html
Source 47: https://www.globenewswire.com/en/news-release/2022/10/25/2541211/0/en/Clinical-Laboratory-Test-Market-Size-Worth-USD-325-Billion-by-2030-at-6-9-CAGR-Report-by-Market-Research-Future-MRFR.html
Source 48: https://www.barchart.com/stocks/quotes/ALBT/price-history/historical
Source 49: https://stockstotrade.com/low-float-stocks/
Source 50: https://www.marketwatch.com/investing/stock/albt?mod=search_symbol
Source 51: https://schrts.co/chEVdrer
Source 52: https://finviz.com/quote.ashx?t=ALBT&p=d
Source 53: https://media.licdn.com/dms/image/C4E12AQExPHCkOpZD6w/article-cover_image-shrink_720_1280/0/1579853356913?e=2147483647&v=beta&t=uK90hCgZUg8v-a-HnPk7ZERDQQxmtljdBrRHWvtSnhM
Recent Posts
Clean Vision Corp (OTC: CLNV): Overcoming the Plastic Waste Crisis
Meta Materials (NASDAQ: MMAT): More Due Diligence and Exploring Latest Developments
Integrated Cannabis Solutions’ (OTC: IGPK) 633% Surge: Exploring Catalysts, Company Overview, and Growth Potential in 2024
Sonoma Pharmaceuticals (NASDAQ: SNOA): Potential Surge to Speculations – What Lies Ahead?
1847 Holdings (NYSE: EFSH) Soars: Insights, Acquisitions, and What Lies Ahead